TNGX News and Press, Tango Therapeutics Inc. From 01/25/24

2024-01-25 12:46:04 ET Summary Tango Therapeutics, a biotech company focused on synthetic lethality and PRMT5 inhibition, has two PRMT5 inhibitors in clinical development. Tango's shares spiked after positive data from Mirati Therapeutics' PRMT5 inhibitor, highlighting the potenti...

2024-01-16 10:00:59 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...

2024-01-12 00:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-07 04:13:27 ET Summary Tango Therapeutics stock experienced a significant increase after positive data from Mirati's synthetic lethality technology. Mirati's data showed promising results in a Phase 1/2 clinical trial of their PRMT5 inhibitor, MRTX1719. Despite the pos...

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study PR Newswire STOCKHOLM , Jan. 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focuse...

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluat...

2023-12-23 07:00:00 ET More on Carvana Carvana: Kicking The Can Down The Road Carvana's Controversial Journey: Why I'm Still Bullish Despite Debt Exchange, Carvana Is Still Not A Buy Auto retail stocks gain after better-than-feared earnings report from CarMax...

– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers – BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to dis...

Tango Therapeutics Inc. (TNGX) is expected to report $-0.34 for Q3 2023

2023-11-08 08:44:56 ET Tango Therapeutics press release ( NASDAQ: TNGX ): Q3 GAAP EPS of -$0.23. Revenue of $10.7M. For further details see: Tango Therapeutics GAAP EPS of -$0.23, revenue of $10.7M